ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2971

Raynaud Phenomenon Subjects with Abnormal Capillary Dilations Show a Risk Threshold Diameter Value for the Transition to the Capillaroscopic Early� Scleroderma Pattern: A Case Control Study

Maurizio Cutolo1, Carmen Pizzorni2, Marianna Meroni2, Vanessa Smith3, Sabrina Paolino2, Barbara Ruaro2, Alberto Sulli2, Bruno Seriolo2 and Amelia Chiara Trombetta2, 1Department of Internal Medicine, University of Genova, Genova, Italy, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, 2Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, 3Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Capillaroscopy, diagnostic imaging and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Nailfold Video Capillaroscopy (NVC) is a reliable method to qualitatively differentiate Primary (PRP) from Secondary Raynaud Phenomenon (SRP) through diagnosis of the “early scleroderma pattern” (1, 2). Quantitative evaluation by NVC was demonstrated to be of great value for the analysis of abnormal capillary parameters (2). The purpose was to assess the presence and localization of capillary diameter abnormalities (>20μm),before the transition to SRP. Moreover, to find a threshold value for those dilations, associated to the development of giant capillaries (>50 μm), pathognomonic for the “early scleroderma pattern” (SSc).

Methods: We realized a case-control study, over a total population of 191 RP subjects with a NVC follow-up of 42.77±35.80 months. Two gruoups were identified, uniform for demographic characteristics (gender, age), RP duration (p= 0.98), treatments (p=0.13) and comorbidities (p=0.13). RP subjects were classified as SRP SSc-associated, based on the appearance of the “early” scleroderma pattern and/or ANA positivity, or confirmed with PRP. One operator performed the NVC and results were separately checked by two experts with an inter-rater/intra-rater proportion of agreement of 90% and 96%, respectively. Another observer measured on NVC images the major dilation of capillary branches (arterial, venous, apical) using a dedicated software (Videocap, DS MediGroup, Milan, Italy). More then 6112 images were analyzed. The mean diameter value for each enlarged branch (arterial, venous, apical) and the total mean diameter, were calculated. Statistics were performed by non-parametric tests. ROC curve was performed to find the SSc development associated threshold value.

Results: A statistically significant difference was found in SRP subjects, before the transition, compared to PRP subjects, for diameter values of dilations in both arterial (35.30 ± 8.79 VS 27.84 ± 5.52 μm; p<0.0001) and venous (37.19 ± 6.58 VS 28.86 ± 4.48 μm; p<0.0001) branches. No significant differences were observed for apical dilations (32.64 ± 5.77 VS 30.81 ± 6.35 μm; p=0.07). ANAs were observed in 56.2% of SRP patients (p= <0.0001). No confounding effect was observed for other demographic and clinical data. Kaplan-Meier analysis showed that 50% of SRP patients evolved to SSc in 20 months. The threshold value associated with SSc development was 30.16 μm, determined through ROC curve, with a sensitivity/specificity of 0.85/0.63 respectively, a negative predictive value (NPV) of 0.92 and a positive predictive value (PPV) of 0.44.

Conclusion: Abnormal dilations of arterial and/or venous branches, at baseline, are detectable by NVC, and are significantly more often expressed in RP subjects that will develop a SRP.Progression to “giant” capillaries (>50 μm) pathognomonic for the “early” NVC scleroderma pattern seem to be unlikely for subjects affected by RP with mean capillary diameter lower then 30.16 μm (NPV 0.92). Therefore, it is advisable to perform always the qualitative/quantitative integrated NVC during the follow up of all patients affected by RP.

References: 1) Cutolo M et al. 2000;27:155–60. 2) Cutolo M et al. Best Pract Res Clin Rheumatol. 2013;27(2):237-48. 3) Smith V at al. J Rheumatol. 2013;40:2023-8


Disclosure: M. Cutolo, None; C. Pizzorni, None; M. Meroni, None; V. Smith, None; S. Paolino, None; B. Ruaro, None; A. Sulli, None; B. Seriolo, None; A. C. Trombetta, None.

To cite this abstract in AMA style:

Cutolo M, Pizzorni C, Meroni M, Smith V, Paolino S, Ruaro B, Sulli A, Seriolo B, Trombetta AC. Raynaud Phenomenon Subjects with Abnormal Capillary Dilations Show a Risk Threshold Diameter Value for the Transition to the Capillaroscopic Early� Scleroderma Pattern: A Case Control Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/raynaud-phenomenon-subjects-with-abnormal-capillary-dilations-show-a-risk-threshold-diameter-value-for-the-transition-to-the-capillaroscopic-early%ef%bf%bd-scleroderma-pattern-a-case-control-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/raynaud-phenomenon-subjects-with-abnormal-capillary-dilations-show-a-risk-threshold-diameter-value-for-the-transition-to-the-capillaroscopic-early%ef%bf%bd-scleroderma-pattern-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology